Clinical Trials Logo

THC clinical trials

View clinical trials related to THC.

Filter by:

NCT ID: NCT04851392 Completed - Cannabis Use Clinical Trials

Do Adolescents and Adults Differ in Their Acute Response to Cannabis?

CannTeenA
Start date: March 11, 2019
Phase: N/A
Study type: Interventional

The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).

NCT ID: NCT04429568 Recruiting - Nicotine Dependence Clinical Trials

THC Crossover Study

TRDRP
Start date: October 30, 2020
Phase: N/A
Study type: Interventional

This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.

NCT ID: NCT04360044 Completed - Migraine Clinical Trials

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

Start date: November 20, 2020
Phase: Phase 2
Study type: Interventional

This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.

NCT ID: NCT04340700 Withdrawn - Vaping Clinical Trials

Characterization of the Pharmacodynamic Response to Vaped THC

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

This study aims to characterize the pharmacodynamic response to vaped THC in young adult, occasional cannabis users with respect to outcomes such as stimulation and sedative effects, mood, anxiety, and craving, as well as cognitive and objective outcomes such as heart rate and cortisol changes with THC vs placebo.

NCT ID: NCT04294966 Completed - Adolescent Behavior Clinical Trials

Age-Related Effects of THC

ART
Start date: March 10, 2020
Phase: Early Phase 1
Study type: Interventional

Increased accessibility to cannabis and its primary psychoactive constituent THC has raised public health concerns. One major concern surrounds the potential risks associated with acute THC intoxication and who might be most at risk. A second major concern is the need to develop sensitive measures that can detect THC intoxication after recent use and enable robust comparisons of intoxication to determine sources of risk. One potential source of risk is age, specifically during the period of adolescence.

NCT ID: NCT04130633 Recruiting - THC Clinical Trials

Behavioral Pharmacology of THC and Alpha-pinene

Start date: November 5, 2020
Phase: Phase 1
Study type: Interventional

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized alpha-pinene and THC administered via inhalation.

NCT ID: NCT03560934 Active, not recruiting - Sleep Clinical Trials

Tetrahydrocannabinol (THC) and Sleep

Start date: September 1, 2018
Phase: Early Phase 1
Study type: Interventional

The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.

NCT ID: NCT03098940 Not yet recruiting - THC Clinical Trials

A Bioavailability Study on Dronabinol

Start date: January 2018
Phase: Phase 1
Study type: Interventional

This study is a two part study

NCT ID: NCT02102113 Active, not recruiting - Schizophrenia Clinical Trials

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

Start date: January 2014
Phase: Early Phase 1
Study type: Interventional

The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.